Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
HUMANIGEN INC (HGEN) Stock Price & Overview
NASDAQ:HGEN • US4448632038
Current stock price
0.0361 USD
-0.16 (-81.12%)
At close:
0.0358 USD
0 (-0.83%)
After Hours:
The current stock price of HGEN is 0.0361 USD. Today HGEN is down by -81.12%. In the past month the price decreased by -76.06%. In the past year, price decreased by -90.16%.
HGEN Key Statistics
52-Week Range0.0358 - 0.4115
Current HGEN stock price positioned within its 52-week range.
1-Month Range0.0358 - 0.207
Current HGEN stock price positioned within its 1-month range.
- Market Cap
- 4.299M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.65
- Dividend Yield
- N/A
HGEN Stock Performance
Today
-81.12%
1 Week
-81.17%
1 Month
-76.06%
3 Months
-77.30%
Longer-term
6 Months -76.54%
1 Year -90.16%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
HGEN Stock Chart
HGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HGEN. When comparing the yearly performance of all stocks, HGEN is a bad performer in the overall market: 99.57% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
HGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HGEN. Both the profitability and financial health of HGEN have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HGEN Earnings
Next Earnings DateAug 10, 2023
Last Earnings DateMay 15, 2023
PeriodQ1 / 2023
EPS Reported-$0.04
Revenue Reported
EPS Surprise 34.64%
Revenue Surprise %
HGEN Forecast & Estimates
6 analysts have analysed HGEN and the average price target is 0.15 USD. This implies a price increase of 323.82% is expected in the next year compared to the current price of 0.0361.
For the next year, analysts expect an EPS growth of 83.55% and a revenue growth -91.42% for HGEN
Analysts
Analysts43.33
Price Target0.15 (315.51%)
EPS Next Y83.55%
Revenue Next Year-91.42%
HGEN Financial Highlights
Over the last trailing twelve months HGEN reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 79.5% compared to the year before.
Income Statements
Revenue(TTM)1.70M
Net Income(TTM)-53.63M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%87.5%
Sales Q2Q%-78.67%
EPS 1Y (TTM)79.5%
Revenue 1Y (TTM)-59.01%
HGEN Ownership
Ownership
Inst Owners0.01%
Shares119.08M
Float106.75M
Ins Owners5.13%
Short Float %N/A
Short RatioN/A
HGEN Industry Overview
HGEN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
HGEN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HGEN
Company Profile
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 6 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The firm has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
Company Info
IPO: 2013-01-30
HUMANIGEN INC
830 Morris Turnpike, 4th Floor
Short Hills NEW JERSEY 94010 US
CEO: Cameron Durrant
Employees: 6
Phone: 19732003100.0
HUMANIGEN INC / HGEN FAQ
What does HGEN do?
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 6 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The firm has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
What is the stock price of HUMANIGEN INC today?
The current stock price of HGEN is 0.0361 USD. The price decreased by -81.12% in the last trading session.
Does HUMANIGEN INC pay dividends?
HGEN does not pay a dividend.
How is the ChartMill rating for HUMANIGEN INC?
HGEN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for HUMANIGEN INC?
HUMANIGEN INC (HGEN) operates in the Health Care sector and the Biotechnology industry.
What is HUMANIGEN INC worth?
HUMANIGEN INC (HGEN) has a market capitalization of 4.30M USD. This makes HGEN a Nano Cap stock.